Watch for HSR clearance and any regulatory challenges to the deal. The earnout structure means OPK retains upside from 4Kscore performance. Post-close, OPKO's remaining business (Excluded Business) will be the primary valuation driver.
Price Chart
Executive Summary
OPKO Health (OPK) has agreed to sell its BioReference clinical and anatomic pathology laboratory testing business, including the 4Kscore prostate cancer test, to Labcorp (Laboratory Corporation of America Holdings) for $722 million in cash at closing, subject to revenue-based adjustments, plus up to $150 million in contingent earnout payments over 10 years based on 4Kscore sales. The transaction is expected to close by April 14, 2027, subject to HSR clearance and other customary conditions, with a $28.88 million termination fee payable by Labcorp if the deal fails due to regulatory issues.
Key Financial Metrics
Key Facts
- OPKO Health agrees to sell its BioReference laboratory testing business to Labcorp for $722 million in cash at closing.
- Up to $150 million in additional contingent earnout payments over 10 years based on 4Kscore prostate cancer test sales.
- Purchase price subject to upward or downward adjustments based on business revenues at closing.
- Transaction expected to close by April 14, 2027, subject to HSR clearance and other customary conditions.
- Labcorp must pay a $28.88 million termination fee if the deal fails due to failure to obtain regulatory approvals.
- The OIG determination (regarding the Corporate Integrity Agreement) has already been obtained.
- OPKO retains its Excluded Business and certain excluded assets post-closing.
Financial Impact
OPKO receives $722 million in cash at closing, plus up to $150 million in earnout payments over 10 years based on 4Kscore revenue. The deal provides significant liquidity and monetizes a non-core asset.
Risk Factors
- HSR clearance or other regulatory approvals may not be obtained, triggering termination or delay.
- Revenue-based purchase price adjustments could reduce the final cash consideration.
- Earnout payments depend on future 4Kscore sales, which may underperform expectations.
- Integration risks for Labcorp and potential customer attrition during transition.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-422877 |
| Document: opk-20261014.htm | 0001193125-26-422877 |
| Document: 0001193125-26-422877-index-headers.html | 0001193125-26-422877 |
| Document: 0001193125-26-422877-index.html | 0001193125-26-422877 |
| Document: 0001193125-26-422877.txt | 0001193125-26-422877 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $1.53 $1.63 | ▲ +6.54% | ▲ +6.97% | $1.61 (+5.23%) |
Jul 27, 2026 13w ago | 8-K | $1.65 $1.31 | ▼ −20.61% | ▼ −22.88% | $1.61 (−2.42%) |
Jul 23, 2026 13w ago | Press Release | $1.17 $1.34 | ▲ +14.10% | ▲ +13.63% | $1.61 (+37.61%) |
Jun 15, 2026 19w ago | Press Release | $1.40 $1.43 | ▲ +2.14% | ▲ +3.53% | $1.61 (+15.00%) |
May 15, 2026 23w ago | DEFA14A | $1.13 $1.29 | ▲ +14.16% | ▲ +12.54% | $1.61 (+42.48%) |
Apr 30, 2026 25w ago | Press Release | $1.13 $1.12 | ▼ −0.89% | ▼ −2.61% | $1.61 (+42.48%) |
Apr 22, 2026 26w ago | Press Release | $1.23 $1.04 | ▼ −15.35% | ▼ −15.40% | $1.61 (+30.89%) |
Apr 21, 2026 27w ago | Press Release | $1.23 $1.04 | ▼ −15.35% | ▼ −15.40% | $1.61 (+30.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers